Elevated lipoprotein (a) levels in hypertensive patients in southern part of Nigeria 10.55131/jphd/2024/220219
Article Sidebar
Main Article Content
Abstract
Hypertension is linked with an increased risk of cardiovascular disease and is the leading modifiable risk factor for morbidity and mortality globally. Lipoprotein (a) is an independent risk factor for atherosclerotic cardiovascular disease. It has been suggested to contribute to increased risk for atherosclerosis in hypertensive patients. This study was to investigate the levels of Lp (a) in hypertensive patients and correlate them with other risk factors of cardiovascular disease. This was a hospital-based cross-sectional study conducted between October 2022 and December 2023 at the Delta State Central Hospital, Warri. The study involved 200 hypertensive patients and 100 healthy controls. The lipoprotein (a) levels in the hypertensives ranged from 5.2 – 89.0 mg/dl with a mean of 32.8 ± 16.6 mg/dl. The controls had a range of 1.1 – 63.2 mg/dl with a mean of 16.9 ± 13.9 mg/dl. The difference in mean Lp(a) levels was statistically significant (p <0.001). In the hypertensives, Lp(a) correlated positively with body weight (r = 0.522, p = 0.001), BMI (r = 0.553, p = 0.002) and waist circumference (r = 0.628, p = 0.001).Serum Lp (a) levels were significantly higher in the hypertensive patients than in the normotensive controls. There was a positive correlation between serum Lp (a) and BMI and waist circumference in the hypertensive group.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
References
Buelt A, Richards A, Jones A. Hypertension: New guidelines from the International Society of Hypertension. Am Fam Physician. 2021; 103(12):763-5.
Oparil S, Acelajado MC, Bakris GL, Berlowitz DR, Cifkova R, Dominiczak AF, et al. Hypertension. Nat Rev Dis Primers. 2018; 4:18014.
Maranhao RC, Carvalho PO, Strunz CC, Pileggi F. Lipoprotein (a): Structure, pathophysiology and clinical implications. Arq Bras Cardiol. 2014;103(1):76-84.
Tangvarasittichai S, Pingmuanglaew P, Tangvarasittichai O. Association of elevated serum lipoprotein (a), inflammation, oxidative stress and chronic kidney disease with hypertension in non-diabetic hypertensive patients. Indian J Clin Biochem. 2016; 31(4):446-51.
Ward NC, Nolde JM, Chan J, Carnagarin R, Watts GF, Schlaich MP. Lipoprotein (a) and hypertension. Curr Hypertens Rep. 2021; 23(12):44.
Saeedi R, Frohlich J. Lipoprotein (a), an independent cardiovascular risk marker. Clin Diabetes Endocrinol. 2016;2:7. doi: 10.1186/s40842-016-0024-x.
Brosolo G, Porto AD, Bulfone L, Vacca A, Bortin N, Colussi G, et al. Plasma lipoprotein (a) levels as determinants of arterial stiffening in hypertension. Biomedicines. 2021; 9(11):1510. doi: 10.3390/ biomedicines9111510.
Tsimikas S, Karwatowska-Prokopezuk E, Gouni-Berthold L, Tardif JC, Baum SJ, Steinhagem-Thressen E, et al. Lipoprotein (a) reduction in persons with cardiovascular disease. N Engl J Med. 2020; 382:244-55. doi: 10.1056/NEJMoa1905239.
Farzam K, Senthikumaran S. Lipoprotein A. [updated 2022 Sep 2]. In: StatPearrls. Treasure Island (FL): StatPearls Publishing. 2022.
Akpan EE, Ekrikpo UE, Udo AI, Bassey BE. Prevalence of Hypertension in Akwa Ibom State, South-South Nigeria: Rural versus Urban Communities Study. Int J Hypertens. 2015;2015:975819. doi: 10.1155/2015/975819
Chukwuonye, II, Ohagwu KA, Ogah OS, John C, Oviasu E, Anyabolu EN, et al. Prevalence of overweight and obesity in Nigeria: Systematic review and meta-analysis of population-based studies. PLOS Glob Public Health. 2022;2(6):e0000515. doi: 10.1371/ journal.pgph.0000515.
O'Donoghue ML, Fazio S, Giugliano RP, Stroes ESG, Kanevsky E, Gouni-Berthold I, et al. Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk. Circulation. 2019;139(12):1483-92. doi: 10.1161/ CIRCULATIONAHA.118.037184
Hoogeveen RC, Ballantyne CM. Residual cardiovascular risk at low LDL: remnants, lipoprotein (a), and inflammation. Clin Chem. 2021; 67(1):143-53. doi: 10.1093/clinchem/ hvaa252.
Jordan J, Kurschat C, Reuter H. Arterial hypertension. Dtsch Arztebl Int. 2018;115(33-34):557-68.
Levey AS, Greene T, Kusek J, Beck G. A simplified equation to predict glomerular filtration rate from serum creatinine. J Am Soc Nephrol. 2000;11:155A.
Papadakis JA, Ganotakis ES, Jagroop IA, Mikhailidis DP, Winder AF. Effect of hypertension and its treatment on lipid, lipoprotein (a), fibrinogen, and bilirubin levels in patients referred for dyslipidemia. American Journal of Hypertension. 1999;12(7):673-81. doi: 10.1016/s0895-7061(99)00049-7.
Mahto SK, Sheoran A, Gadpayle AK, Gupta K, Gupta PK, Chitkarn A, et al. Evaluation of lipoprotein (a) and lipid abnormalities in patients with newly detected hypertension and its association with severity of hypertension. J Family Med Prim Care. 2022; 11(4):1508-13. doi: 10.4103/ jfmpc.jfmpc_989_21.
Sur A, Tirkey BN, Mishra PK. Evaluation of role of serum lipoprotein and lipid profile in essential hypertension patients in a tertiary care hospital. J Hypertens. 2015;4:204.
Bhavani BA, Padma T, Sastry BKS, Reddy NK. Plasma lipoprotein (a) levels in patients with untreated essential hypertension. Indian Journal of Human Genetics. 2003;9(2).
Rikhi R, Bhatra HS, Schaich CL, Ashburn N, Tsai MY, Michos ED, Chevli PA, et al. Association of lipoprotein (a) and hypertension in primary prevention of cardiovascular disease: The MESA. Hypertension. 2023;80:352-60. doi: 10.1161/ HYPERTENSIONAHA.122.20189.
European Atherosclerosis Society (EAS), new recommendations from the European Atherosclerosis Society consensus panel resolve controversy about lipoprotein (a) and cardiovascular risk. 2010. Available from: http://www.diabetesincontrol. com/european-atherosclerosis-society-recommends-screening-for-lpa/[Ref list].
Gannagé-Yared MH, Lahoud C, Younes N, Chedid R, Sleilaty G. Prevalence and status of Lipoprotein (a) among Lebanese school children. Sci Rep. 2020;10(1):20620. doi: 10.1038/s41598-020-77689-5.
Stuerzebecher P, Kiess W, Koerner A, Laufs U. Lipoprotein (a) serum concentrations in children are not affected by age, sex or body mass index. Circulation. 2021;144A11934.
Posadas-Romero C, Hernández-Ono A, Zamora-González J, Cardoso-Saldaña G, Yamamoto-Kimura L, Brito-Zurita OR. Differential effects of obesity with and without hyperinsulinemia on plasma lipoprotein(a) concentrations in men. Metabolism. 2001;50(2):178-83. doi: 10.1053/meta.2001.20195.
Pino BD, Gorini F, Gaggini M, Landi P, Pingitore A, Vassalle C. Lipoprotein(a), Cardiovascular Events and Sex Differences: A Single Cardiological Unit Experience. J Clin Med. 2023;12(3). doi: 10.3390/ jcm12030764.
Markus MRP, Ittermann T, Schipf S, Bahls M, Nauck M, Völzke H, et al. Association of sex-specific differences in lipoprotein(a) concentrations with cardiovascular mortality in individuals with type 2 diabetes mellitus. Cardiovasc Diabetol. 2021;20(1):168. doi: 10.1186/s12933-021-01363-x.
Teng RL, Wang H, Sun BC, Cai DP, He YM. Interaction between lipoprotein (a) levels and body mass index in first incident acute myocardial infarction. BMC Cardiovasc Disord. 2020;20(1):350. doi: 10.1186/s12872-020-01626-7.
Kaltoft M, Langsted A, Afzal S, Kamstrup PR, Nordestgaard BG. Lipoprotein(a) and Body Mass Compound the Risk of Calcific Aortic Valve Disease. J Am Coll Cardiol. 2022;79(6):545-58. doi: 10.1016/ j.jacc.2021.11.043.